Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Patent metadata

Field	Value
Publication number	US-9441044-B2
Application number	US-201514645282-A
Country	US
Kind code	B2
Filing date	Mar 11, 2015
Priority date	Mar 5, 2010
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.

First claim

What is claimed is:

1. An isolated molecule comprising a targeting moiety fused with an immunomodulatory moiety, wherein:
(a) the targeting moiety specifically binds Epidermal Growth Factor Receptor (EGFR); and
(b) the immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor II (TGF-βRII).

2. The molecule of claim 1 , wherein the targeting moiety comprises an antibody, antibody fragment, scFv, or Fc-containing polypeptide that specifically binds EGFR or a fragment thereof.

3. The molecule of claim 1 , wherein the immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor selected from the group consisting of SEQ ID NO: 79-91.

4. The molecule of claim 3 , wherein the immunomodulatory moiety comprises the amino acid sequence corresponding to SEQ ID NO: 87 or a binding fragment thereof.

5. The molecule of claim 4 , wherein the molecule comprises the amino acid sequence corresponding to SEQ ID NO: 2 or a binding fragment thereof.

6. The molecule of claim 5 , wherein the molecule comprises the amino acid sequence corresponding to SEQ ID NO: 2 or a binding fragment thereof and the amino acid sequence corresponding to SEQ ID NO: 71 or a binding fragment thereof.

7. The isolated molecule of claim 1 , further comprising a linker at the CH3 region of the Fc.

8. The isolated molecule of claim 7 , wherein the linker is (GGGGS) n (SEQ ID NO:104) n and wherein n is 1, 2, 3, 4, 5, 6, 7 or 8.

9. The isolated molecule of claim 7 , wherein the linker comprises the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO:104).

10. An isolated molecule comprising a targeting moiety fused with an immunomodulatory moiety, wherein:
(a) the targeting moiety specifically binds Epidermal Growth Factor Receptor (EGFR); and
(b) the immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor (TGF-βR).

Assignees

• Univ Johns Hopkins

Inventors

• Bedi Atul
• Ravi Rajani

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title